Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07797855
PHASE1

A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, target engagement, and metabolism of NNC0705-0002 after single and multiple doses in healthy adults. NNC0705-0002 or a placebo (a substance that looks like the study medicine but contains no active medicine), and the treatment they receive may be chosen by chance. NNC0705-0002 is a new medicine that is not yet approved for doctors to prescribe. Depending on the part of the study, participation may last for up to about 7 weeks, including screening, treatment, and follow-up visits.

Official title: A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Target Engagement, and Absorption, Metabolism and Excretion of NNC0705-0002 Following Single and Multiple Oral Administrations of NNC0705-0002 in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

112

Start Date

2026-09-02

Completion Date

2027-08-01

Last Updated

2026-09-30

Healthy Volunteers

Yes

Interventions

DRUG

NNC0705-0002

Participants will receive oral capsule of NNC0705-0002.

DRUG

Placebo

Participants will receive oral capsule of placebo matched to NNC0705-0002.

Locations (1)

ICON - location Groningen

Groningen, Netherlands